2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sikander Ailawadhi, MD, discusses the examination of iopofosine I-131 (CLR 131) in Waldenström macroglobulinemia.
Sikander Ailawadhi, MD, professor of Medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, consultant, Department of Cancer Biology, lead, International Cancer Center, Mayo Clinic, discusses the examination of iopofosine I-131 (CLR 131) in Waldenström macroglobulinemia.
The phase 1 CLOVER-1 trial (NCT02952508) evaluated iopofosine I-131 in patients with various B-cell malignancies, including Waldenström macroglobulinemia, who received prior treatment with standard-of-care therapy. The phase 2 CLOVER-WaM trial is a pivotal expansion of the study, which will further investigate the efficacy of the administration of iopofosine I-131 in patients with Waldenström macroglobulinemia who have received at least 2 prior lines of therapy.
During CLOVER-1, patients with Waldenström macroglobulinemia achieved deep responses, despite being a heavily pretreated population, Ailawadhi says. Complete responses (CRs) were observed among the responders, including 1 patient with Waldenström Macroglobulinemia who remained disease free for multiple years following a CR, Ailawadhi explains.
Results from the phase 1 trial prompted further investigation of iopofosine I-131 in patients with Waldenström macroglobulinemia, Ailawadhi continues. On the trial, patients will receive 4 total administrations of iopofosine I-131, with 2 fractionated doses administered 2 weeks apart, followed by another 2 fractionated doses 8-12 weeks later, dependent on patient tolerance, Ailawadhi concludes.